Metabotropic glutamate receptor modulation, translational methods, and biomarkers: Relationships with anxiety

Psychopharmacology

Volumn 199, Issue 3, 2008, Pages 389-402

  Nordquist, R E ^a,c   Steckler, T ^b   Wettstein, J G ^a   Mackie, C ^b   Spooren, W ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Allometric scaling; Anxiety; Biomarker; Fear potentiated startle; HPA axis; Imaging; Metabotropic glutamate receptor; Stress induced hyperthermia; Translational models

Indexed keywords

ABP 688; ABP 688 C 11; ALLYLGLYCINE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; BUSPIRONE; DIAZEPAM; EGLUMETAD; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MGS 0028; TRACER;

ANXIETY DISORDER; DRUG RECEPTOR BINDING; FEAR; HUMAN; HYPERTHERMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MEDICAL RESEARCH; NONHUMAN; PANIC; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; STARTLE REFLEX; STRESS;

ANIMALS; ANXIETY; BIOLOGICAL MARKERS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 46649093145     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-008-1096-9     Document Type: Review

References (145)

1. Abelson JL, Curtis GC (1996) Hypothalamic-pituitary-adrenal axis activity in panic disorder. 24-h secretion of corticotropin and cortisol. Arch Gen Psychiatry 53:323-331
2. Ametamey SM, Samnick S, Leenders KL, Vontobel P, Quack G, Parsons CG, Schubiger PA (1999) Fluorine-18 radiolabelling, biodistribution studies and preliminary PET evaluation of a new memantine derivative for imaging the NMDA receptor. J Recept Signal Transduct Res 19:129-141
3. Ametamey SM, Kessler LJ, Honer M, Wyss MT, Buck A, Hintermann S, Auberson YP, Gasparini F, Schubiger PA (2006) Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. J Nucl Med 47:698-705
4. Ametamey SM, Treyer V, Streffer J, Wyss MT, Schmidt M, Blagoev M, Hintermann S, Auberson Y, Gasparini F, Fischer UC, Buck A (2007) Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J Nucl Med 48:247-252
5. Angst J, Gamma A, Endrass J, Hantouche E, Goodwin R, Ajdacic V, Eich D, Rössler W (2005) Obsessive-compulsive syndromes and disorders. Eur Arch Psychiatry Clin Neurosci 255:65-71
6. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL, Downing GJ, Hoth DF, Oates JA, Peck CC, Schooley RT, Spilker BA, Woodcock J, Zeger SL (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. 69:89-95
7. Baas J, Grillon C, Böcker K, Brack A, Morgan C, Kenemans L, Verbaten M (2002) Benzodiazepines have no effect on fear-potentiated startle in humans. Psychopharmacology 161:233-247
8. 2 on HPA axis activation in healthy volunteers. J Psychopharmacol 21(Suppl.):A11
9. Ballard TM, Woolley ML, Prinssen E, Huwyler J, Porter R, Spooren W (2005) The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison. Psychopharmacology (Berl) 179:218-229
10. Barros M, Tomaz C (2002) Non-human primate models for investigating fear and anxiety. Neurosci Biobehav Rev 26:187-201
11. Battaglia M, Ogliari A (2005) Anxiety and panic: from human studies to animal research and back. Neurosci Biobehav Rev 29:169-179
12. Beer B, Migler B (1975) Effects of diazepam on galvanic skin response and conflict in monkeys and humans. In: Sudilovsky A, Gershon S, Beer B (eds) Predictability in psychopharmacology: preclinical and clinical correlations. Raven, New York
13. Bergink V, van Megen HJ, Westenberg HG (2004) Glutamate and anxiety. Eur Neuropsychopharmacol 14:175-183
14. Bitsios P, Philpott A, Langley RW, Bradshaw CM, Szabadi E (1999) Comparison of the effects of diazepam on the fear-potentiated startle reflex and the fear-inhibited light reflex in man. J Psychopharmacol 13:226-234
15. Borsini F, Podhorna J, Marazziti D (2002) Do animal models of anxiety predict anxiolytic-like effects of antidepressants. Psychopharmacology (Berl) 163:121-141
16. Bottlaender M, Brouillet E, Varastet M, Le Breton C, Schmid L, Fuseau C, Sitbon R, Crouzel C, Maziere M (1994) In vivo high intrinsic efficacy of triazolam: a positron emission tomography study in nonhuman primates. J Neurochem 62:1102-1111
17. Bouwknecht JA, Olivier B, Paylor RE (2007) The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse. Neurosci Biobehav Rev 31:41-59
18. Boxenbaum H (1982) Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. J Pharmacokinet Biopharmaceut 10:201-227
19. Boxenbaum H, DiLea C (1995) First-time-in-human dose selection: allometric thoughts and perspectives. J Clin Pharmacol 35:957-966
20. Bradbury MJ, Giracello DR, Chapman DF, Holtz G, Schaffhauser H, Rao SP, Varney MA, Anderson JJ (2003) Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: interaction with serotonergic systems. Neuropharmacology 44:562-572
21. Bradwejn J, Koszycki D (2001) Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 234:19-27
22. Briese E (1995) Emotional hyperthermia and performance in humans. Physiol Behav 58:615-618
23. Bueno AB, Collado I, de Dios A, Dominguez C, Martin JA, Martin LM, Martinez-Grau MA, Montero C, Pedregal C, Catlow J, Coffey DS, Clay MP, Dantzig AH, Lindstrom T, Monn JA, Jiang H, Schoepp DD, Stratford RE, Tabas LB, Tizzano JP, Wright RA, Herin MF (2005) Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. J Med Chem 48:5305-5320
24. Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, Tehrani L, Bristow LJ, Varney MA, Cosford ND (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl] pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29:1971-1979
25. Chin CL, Fox GB, Hradil VP, Osinski MA, McGaraughty SP, Skoubis PD, Cox BF, Luo Y (2006) Pharmacological MRI in awake rats reveals neural activity in area postrema and nucleus tractus solitarius: relevance as a potential biomarker for detecting drug-induced emesis. Neuroimage 33:1152-1160
26. Curtis GC, Abelson JL, Gold PW (1997) Adrenocorticotropic hormone and cortisol responses to corticotropin-releasing hormone: changes in panic disorder and effects of alprazolam treatment. Biol Psychiatry 41:76-85
27. Daggett LP, Sacaan AI, Akong M, Rao SP, Hess SD, Liaw C, Urrutia A, Jachec C, Ellis SB, Dreessen J, Knopfel T, Landwehrmeyer GB, Testa CM, Young AB, Varney M, Johnson EC, Velicelebi G (1995) Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5. Neuropharmacology 34:871-886
28. De Boer SF, Van der Gugten J, Slangen JL (1990) Brain benzodiazepine receptor-mediated effects on plasma catecholamine and corticosterone concentrations in rats. Brain Res Bull 24:843-847
29. De Boer SF, Slangen JL, Van der Gugten J (1991a) Effects of buspirone and chlordiazepoxide on plasma catecholamine and corticosterone levels in stressed and nonstressed rats. Pharmacol Biochem Behav 38:299-308
30. De Boer SF, Van der Gugten J, Slangen JL (1991b) Effects of chlordiazepoxide, flumazenil and DMCM on plasma catecholamine and corticosterone concentrations in rats. Pharmacol Biochem Behav 38:13-19
31. Denys D, de Geus F (2005) Predictors of pharmacotherapy response in anxiety disorders. Curr Psychiatry Rep 7:252-257
32. Di Giusto EL, Bond NW (1978) One-trial conditioned suppression: effects of instructions on extinction. Am J Psychol 91:313-319
33. 2/3 agonist in the treatment of generalized anxiety disorder. Neuropsychopharmacology, in press
34. Duong TQ (2007) Cerebral blood flow and BOLD fMRI responses to hypoxia in awake and anesthetized rats. Brain Res 1135:186-194
35. Eser D, Schule C, Baghai T, Floesser A, Krebs-Brown A, Enunwa M, de la Motte S, Engel R, Kucher K, Rupprecht R (2007) Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology (Berl) 192:479-487
36. Feng MR, Lou X, Brown RR, Hutchaleelaha A (2000) Allometric pharmacokinetic scaling: towards the prediction of human oral pharmacokinetics. Pharm Res 17:410-418
37. Fuchs E, Flügge G (2006) Experimental animal models for the simulation of depression and anxiety. Dialogues Clin Neurosci 8:323-333
38. Gale C, Davidson O (2007) Generalised anxiety disorder. BMJ 334:579-581
39. Gellert I, Seifter J (1960) The effects of meprobamate, barbiturates, d-amphetamine and promazine on experimentally induced conflict in the rat. Psychopharmacologia 1:482-492
40. Goodwin RD, Gotlib IH (2004) Panic attacks and psychopathology among youth. Acta Psychiatrica Scandinavica 109:216-221
41. Grillon C, Baas J (2003) A review of the modulation of the startle reflex by affective states and its application in psychiatry. Clin Neurophysiol 114:1557-1579
42. Grillon C, Ameli R, Goddard A, Woods SW, Davis M (1994) Baseline and fear-potentiated startle in panic disorder patients. Biol Psychiatry 35:431-439
43. Grillon C, Dierker L, Merikangas KR (1998a) Fear-potentiated startle in adolescent offspring of parents with anxiety disorders. Biol Psychiatry 44:990-997
44. Grillon C, Morgan CA III, Davis M, Southwick SM (1998b) Effect of darkness on acoustic startle in vietnam veterans with PTSD. Am J Psychiatry 155:812-817
45. Grillon C, Morgan CA III, Davis M, Southwick SM (1998c) Effects of experimental context and explicit threat cues on acoustic startle in vietnam veterans with posttraumatic stress disorder. Biol Psychiatry 44:1027-1036
46. Grillon C, Cordova J, Levine LR, Morgan CA 3rd (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 168:446-454
47. Hanson HM, Witoslawski JJ, Campbell EH (1967) Drug effects in squirrel monkeys trained on a multiple schedule with a punishment contingency. J Exper Anal Behav 10:565-569
48. Helton DR, Tizzano JP, Monn JA, Schoepp DD, Kallman MJ (1998) Anxiolytic and side-effect profile of LY354740: a potent, highly selective, orally active agonist for group II metabotropic glutamate receptors. J Pharmacol Exp Ther 284:651-660
49. Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A (1987) Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Horm Metab Res Suppl 16:80-88
50. Hösing VG, Schirmacher A, Kuhlenbaumer G, Freitag C, Sand P, Schlesiger C, Jacob C, Fritze J, Franke P, Rietschel M, Garritsen H, Nöthen MM, Fimmers R, Stogbauer F, Deckert J (2004) Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. J Neural Transm Suppl 68:147-156
51. Hosoi R, Matsumura A, Mizokawa S, Tanaka M, Nakamura F, Kobayashi K, Watanabe Y, Inoue O (2005) MicroPET detection of enhanced 18F-FDG utilization by PKA inhibitor in awake rat brain. Brain Res 1039:199-202
52. Ising M, Zimmermann US, Kunzel HE, Uhr M, Foster AC, Learned-Coughlin SM, Holsboer F, Grigoriadis DE (2007) High-affinity CRF(1) receptor antagonist NBI-34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 32:1941-1949
53. James JK, Nakamura M, Nakazato A, Zhang KE, Cramer M, Brunner J, Cook J, Chen WG (2005) Metabolism and disposition of a potent group II metabotropic glutamate receptor agonist, in rats, dogs, and monkeys. Drug Metab Dispos 33:1373-1381
54. Jerabek I, Boulenger J-P, Bradwejn J, Drumheller A, Lavallee Y-J, Jolicoeur FB (1999a) CCK4-induced panic in healthy subjects II: neurochemical correlates. Eur Neuropsychopharmacol 9:157-164
55. Jerabek I, Boulenger J-P, Bradwejn J, Lavallee Y-J, Jolicoeur FB (1999b) CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol 9:149-155
56. Jezova D (2005) Control of ACTH secretion by excitatory amino acids: functional significance and clinical implications. Endocrine 28:287-294
57. Johnson MP, Kelly G, Chamberlain M (2001) Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists. J Neuroendocrinol 13:670-677
58. Johnson MP, Baez M, Jagdmann GE Jr, Britton TC, Large TH, Callagaro DO, Tizzano JP, Monn JA, Schoepp DD (2003) Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl) pyrid-3-ylmethylamine. J Med Chem 46:3189-3192
59. Johnson MP, Barda D, Britton TC, Emkey R, Hornback WJ, Jagdmann GE, McKinzie DL, Nisenbaum ES, Tizzano JP, Schoepp DD (2005) Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 179:271-283
60. Kassiou M, Loc'h C, Bottlaender M, Mardon K, Ottaviani M, Coulon C, Katsifis A, Maziere B (2002) (+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nucl Med Biol 29:295-302
61. Kellner M, Muhtz C, Stark K, Yassouridis A, Arlt J, Wiedemann K (2005) Effects of a metabotropic glutamate(2/3) receptor agonist (LY544344/LY354740) on panic anxiety induced by cholecystokinin tetrapeptide in healthy humans: preliminary results. Psychopharmacology (Berl) 179:310-315
62. Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J, Fourie O (1999) Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 4:284-285
63. Kew JN, Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179:4-29
64. Klein DF (1993) False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 50:306-317
65. Klein DF (1994) Testing the suffocation false alarm theory of panic disorder. Anxiety 1:1-7
66. Klodzinska A, Tatarczynska E, Chojnacka-Wojcik E, Nowak G, Cosford NDP, Pilc A (2004) Anxiolytic-like effects of MTEP, a potent and selective mGlu5 receptor agonist does not involve GABAA signaling. Neuropharmacology 47:342-350
67. Kudielka BM, Buske-Kirschbaum A, Hellhammer DH, Kirschbaum C (2004a) HPA axis responses to laboratory psychosocial stress in healthy elderly adults, younger adults, and children: impact of age and gender. Psychoneuroendocrinology 29:83-98
68. Kudielka BM, Schommer NC, Hellhammer DH, Kirschbaum C (2004b) Acute HPA axis responses, heart rate, and mood changes to psychosocial stress (TSST) in humans at different times of day. Psychoneuroendocrinology 29:983-992
69. Lahti KM, Ferris CF, Li F, Sotak CH, King JA (1998) Imaging brain activity in conscious animals using functional MRI. J Neurosci Methods 82:75-83
70. Letwin NE, Kafkafi N, Benjamini Y, Mayo C, Frank BC, Luu T, Lee NH, Elmer GI (2006) Combined application of behavior genetics and microarray analysis to identify regional expression themes and gene-behavior associations. J. Neurosci 26:5277-5287
71. 2 challenge in patients diagnosed with panic disorder. Neuropharmacology 43:294-295
72. 11C]Ro15 4513 positron emission tomography. J Cereb Blood Flow Metab 22:878-889
73. Logothetis NK, Guggenberger H, Peled S, Pauls J (1999) Functional imaging of the monkey brain. Nat Neurosci 2:555-562
74. MacKinnon DF, Zamoiski R (2006) Panic comorbidity with bipolar disorder: what is the manic-panic connection. Bipolar Disorders 8:648-664
75. Maddock RJ (2001) The Lactic Acid Response to Alkalosis in Panic Disorder: an integrative review. J Neuropsychiatry Clin Neurosci 13:22-34
76. Mahmood I (2002) Interspecies scaling: predicting oral clearance in humans. Am J Ther 9:35-42
77. Mahmood I, Balian JD (1996) Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica. 26:887-895
78. Mahmood I, Green MD, Fisher JE (2003) Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J Clin Pharmacol 43:692-697
79. Marazziti D, Di Muro A, Castrogiovanni P (1992) Psychological stress and body temperature changes in humans. Physiol Behav 52:393-395
80. Matheson GK, Raess BU, Tunnicliff G (1996) Effects of repeated doses of azapirones on rat brain 5-HT1A receptors and plasma corticosterone levels. Gen Pharmacol 27:355-361
81. 11C]raclopride and the beta-microprobe: crossvalidation with in vitro binding data. J Cereb Blood Flow Metab 25:1517-1527
82. Mendrick DL (2007) Current trends and strategic directions in the use of pharmacogenomics to identify translational biomarkers. Curr Opin Drug Discov Devel 10:37-42
83. Mildvan D, Landay A, De Gruttola V, Machado SG, Kagan J (1997) An approach to the validation of markers for use in AIDS clinical trials. Clin Infect Dis 24:764-774
84. Millan MJ, Brocco M (2003) The Vogel conflict test: procedural aspects, [gamma]-aminobutyric acid, glutamate and monoamines. Eur J Pharmacol 463:67-96
85. Momosaki S, Hatano K, Kawasumi Y, Kato T, Hosoi R, Kobayashi K, Inoue O, Ito K (2004) Rat-PET study without anesthesia: anesthetics modify the dopamine D1 receptor binding in rat brain. Synapse 54:207-213
86. Moon C-H, Fukuda M, Park S-H, Kim S-G (2007) Neural interpretation of blood oxygenation level-dependent fMRI maps at submillimeter columnar resolution. J Neurosci 27:6892-6902
87. Morgan CA III, Grillon C, Southwick SM, Davis M, Charney DS (1995) Fear-potentiated startle in posttraumatic stress disorder. Biol Psychiatry 38:378-385
88. Nelson JB, del Carmen Sanjuan M (2006) A context-specific latent inhibition effect in a human conditioned suppression test. The Q J Exp Psychol 59:1003-1020
89. 2 receptor in competition with haloperidol and endogenous dopamine-an in vivo imaging study with a dedicated small animal SPECT. Eur J Nucl Med Mol Imaging 32:1305-1310
90. Nordquist RE, Durkin S, Jaeschke G, Spooren W (2007) Stress-induced hyperthermia: effects of acute and repeated dosing of MPEP. Eur J Pharmacol 568:199-202
91. Nutt D, Argyropoulos S, Hood S, Potokar J (2006) Generalized anxiety disorder: a comorbid disease. Eur Neuropsychopharmacol 16:S109-S118
92. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Macintyre F, Rance DJ, Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58
93. Otte C, Kellner M, Arlt J, Jahn H, Holsboer F, Wiedemann K (2002) Prolactin but not ACTH increases during sodium lactate-induced panic attacks. Psychiatry Res 109:201-205
94. Pain F, Besret L, Vaufrey F, Gregoire M-C, Pinot L, Gervais P, Ploux L, Bloch G, Mastrippolito R, Laniece P, Hantraye P (2002) In vivo quantification of localized neuronal activation and inhibition in the rat brain using a dedicated high temporal-resolution beta+-sensitive microprobe. PNAS 99:10807-10812
95. Parsons CG, Stoffler A, Danysz W (2007) Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology 53:699-723
96. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Furst DE, Harter JG, Levy G, Ludden T, Rodman JH et al (1994) Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Clin Pharmacol 34:111-119
97. Peeters RR, Tindemans I, De Schutter E, Van der Linden A (2001) Comparing BOLD fMRI signal changes in the awake and anesthetized rat during electrical forepaw stimulation. Magn Reson Imaging 19:821-826
98. Perel P, Roberts I, Sena E, Wheble P, Briscoe C, Sandercock P, Macleod M, Mignini LE, Jayaram P, Khan KS (2007) Comparison of treatment effects between animal experiments and clinical trials: systematic review. Br Med J 334:197
99. 5 receptor antagonists in rats. Eur J Pharmacol 514:25-34
100. Pilc A, Klodzinska A, Branski P, Nowak G, Palucha A, Szewczyk B, Tatarczynska E, Chojnacka-Wojcik E, Wieronska JM (2002) Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43:181-187
101. Rassovsky Y, Kushner MG (2003) Carbon dioxide in the study of panic disorder: issues of definition, methodology, and outcome. J Anxiety Disord 17:1-32
102. Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, Barbanoj M (2001) Differential effects of alprazolam on the baseline and fear-potentiated startle reflex in humans: a dose-response study. Psychopharmacology 157:358-367
103. Risbrough VB, Stein MB (2006) Role of corticotropin releasing factor in anxiety disorders: a translational research perspective. Horm Behav 50:550-561
104. Romano C, Sesma MA, McDonald CT, O'Malley K, van den Pol AN, Olney JW (1995) Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. The J Comp Neurol 355:455-469
105. Rorick-Kehn LM, Hart JC, McKinzie DL (2005) Pharmacological characterization of stress-induced hyperthermia in DBA/2 mice using metabotropic and ionotropic glutamate receptor ligands. Psychopharmacology (Berl) 183:226-240
106. Rorick-Kehn LM, Perkins EJ, Knitowski KM, Hart JC, Johnson BG, Schoepp DD, McKinzie DL (2006) Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344. J Pharmacol Exp Ther 316:905-913
107. Rorick-Kehn LM, Johnson BG, Burkey JL, Wright RA, Calligaro DO, Marek GJ, Nisenbaum ES, Catlow JT, Kingston AE, Giera DD, Herin MF, Monn JA, McKinzie DL, Schoepp DD (2007) Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2- sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039). J Pharmacol Exp Ther 321:308-317
108. Roy-Byrne PP, Uhde TW, Post RM, Gallucci W, Chrousos GP, Gold PW (1986) The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 143:896-899
109. Roy-Byrne PP, Craske MG, Stein MB (2006) Panic disorder. Lancet 368:1023-1032
110. Sajdyk TJ, Shekhar A (2000) Sodium lactate elicits anxiety in rats after repeated GABA receptor blockade in the basolateral amygdala. Eur J Pharm 394:265-273
111. Salgado JV, Vidal M, Oberling P, Graeff FG, Danion JM, Sandner G (2000) Associative learning and latent inhibition in a conditioned suppression paradigm in humans. Behav Brain Res 117:53-60
112. Scaife JC, Langley RW, Bradshaw CM, Szabadi E (2005) Diazepam suppresses the acquisition but not the expression of 'fear potentiation' of the acoustic startle response in man. J Psychopharmacol 19:347-356
113. Scaife JC, Hou RH, Samuels ER, Baqui F, Langley RW, Bradshaw CM, Szabadi E (2007) Diazepam-induced disruption of classically-conditioned fear-potentiation of late-latency auditory evoked potentials is prevented by flumazenil given before, but not after, CS/US pairing. J Psychopharmacol 21:93-101
114. Schruers K, Pols H, Overbeek T, Griez E (2000) 10mG CCK-4 premedication and 35% CO2 challenge in healthy volunteers. Prog Neuro-Psychopharmacol Biol Psychiatry 24:409-418
115. Sepinwall J, Grodsky FS, Cook L (1978) Conflict behavior in the squirrel monkey: effects of chlordiazepoxide, diazepam and N-desmethyldiazepam. J Pharmacol Exp Ther 204:88-102
116. 5 receptors. Nucl Med Biol 33:1021-1027
117. Shekhar A, Keim SR (2000) LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 39:1139-1146
118. Shekhar A, Keim SR, Simon JR, McBride WJ (1996) Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol Biochem Behav 55:249-256
119. Singer JB, Hill AE, Nadeau JH, Lander ES (2005) Mapping quantitative trait loci for anxiety in chromosome substitution strains of mice. Genetics 169:855-862
120. Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RAHJ, Van Peer A, Lavrijsen K, Mackie CE (2008) Predicting oral clearance in humans-how close can we get with allometry. Clin Pharacokinet 47:35-45
121. Skoubis PD, Hradil V, Chin CL, Luo Y, Fox GB, McGaraughty S (2006) Mapping brain activity following administration of a nicotinic acetylcholine receptor agonist, ABT-594, using functional magnetic resonance imaging in awake rats. Neuroscience 137:583-591
122. Smitherman TA (2005) Challenge tests and panic disorder: implications for clinical assessment. Prof Psychol Res Pract 36:510-516
123. Spooren W, Gasparini F (2004) mGlu5 receptor antagonists: a novel class of anxiolytics. Drug News Perspect 17:251-257
124. Spooren WP, Gasparini F, Salt TE, Kuhn R (2001) Novel allosteric antagonists shed light on mglu(5) receptors and CNS disorders. Trends Pharmacol Sci 22:331-337
125. Spooren WP, Schoeffter P, Gasparini F, Kuhn R, Gentsch C (2002) Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur J Pharmacol 435:161-170
126. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R (2003) Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277
127. Stachowicz K, Golembiowska K, Sowa M, Nowak G, Chojnacka-Wojcik E, Pilc A (2007) Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent. Neuropharmacology 53:741-748
128. Steckler T (2007) Peptide receptor ligands to treat anxiety disorders. In: Griebel G, Blanchard C, Blanchard B (eds) Handbook of fear and anxiety. Elsevier, New York
129. Steckler T, Lavreysen H, Oliveira AM, Aerts N, Van Craenendonck H, Prickaerts J, Megens A, Lesage AS (2005a) Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology (Berl) 179:198-206
130. Steckler T, Oliveira AF, Van Dyck C, Van Craenendonck H, Mateus AM, Langlois X, Lesage AS, Prickaerts J (2005b) Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav Brain Res 164:52-60
131. Steckler T, Stein MB, Holmes A (2007) Developing novel anxiolytics: improving preclinical detection and clinical assessment. In: McArthur RA, Borsini F (eds) Animal and translational models of behavioural disorders. Elsevier, New York
132. Swanson CJ, Bures M, Johnson MP, Linden AM, Monn JA, Schoepp DD (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat Rev Drug Discov 4:131-144
133. Tang H, Mayersohn M (2005) A novel model for prediction of human clearance by allometric scaling. Drug Metab Dispos 33:1297-1303
134. Tizzano JP, Griffey KI, Schoepp DD (2002) The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle model in rats is mechanistically distinct from diazepam. Pharmacol Biochem Behav 73:367-374
135. Unger EF (2007) All is not well in the world of translational research. J Am Coll Cardiol 50:738-740
136. Valdar W, Solberg LC, Gauguier D, Burnett S, Klenerman P, Cookson WO, Taylor MS, Rawlins JNP, Mott R, Flint J (2006) Genome-wide genetic association of complex traits in heterogeneous stock mice. Nat Genet 38:879-887
137. 2 challenge results in hypothalamic-pituitary-adrenal activation in healthy volunteers. J Psychopharmacol 19:243-247
138. 2 challenge induced HPA axis activation in panic. Int J Neuropsychopharmacol 10:797-804
139. van Megen HJ, Westenberg HG, den Boer JA, Kahn RS (1996) Cholecystokinin in anxiety. Eur Neuropsychopharmacol 6:263-280
140. Varty GB, Grilli M, Forlani A, Fredduzzi S, Grzelak ME, Guthrie DH, Hodgson RA, Lu SX, Nicolussi E, Pond AJ, Parker EM, Hunter JC, Higgins GA, Reggiani A, Bertorelli R (2005) The antinociceptive and anxiolytic-like effects of the metabotropic glutamate receptor 5 (mGluR5) antagonists, MPEP and MTEP, and the mGluR1 antagonist, LY456236, in rodents: a comparison of efficacy and side-effect profiles. Psychopharmacology (Berl) 179:207-217
141. Walker DL, Rattiner LM, Davis M (2002) Group II metabotropic glutamate receptors within the amygdala regulate fear as assessed with potentiated startle in rats. Behav Neurosci 116:1075-1083
142. Wehling M (2006) Translational medicine: can it really facilitate the transition of research "from bench to bedside". Eur J Clin Pharmacol 62:91-95
143. Wray NR, James MR, Mah SP, Nelson M, Andrews G, Sullivan PF, Montgomery GW, Birley AJ, Braun A, Martin NG (2007) Anxiety and comorbid measures associated with PLXNA2. Arch Gen Psychiatry 64:318-326
144. Wyss MT, Ametamey SM, Treyer V, Bettio A, Blagoev M, Kessler LJ, Burger C, Weber B, Schmidt M, Gasparini F, Buck A (2007) Quantitative evaluation of 11C-ABP688 as PET ligand for the measurement of the metabotropic glutamate receptor subtype 5 using autoradiographic studies and a beta-scintillator. Neuroimage 35:1086-1092
145. Zvolensky MJ, Eifert GH (2001) A review of psychological factors/processes affecting anxious responding during voluntary hyperventilation and inhalations of carbon dioxide-enriched air. Clin Psychol Rev 21:375-400